[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse BGN

Summary
SymbolBGN
Namebiglycan
Aliases DSPG1; SLRR1A; biglycan proteoglycan; PG-S1; bone/cartilage proteoglycan I; bone/cartilage proteoglycan-I; d ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted, extracellular space, extracellular matrix
Domain PF13855 Leucine rich repeat
PF01462 Leucine rich repeat N-terminal domain
Function

May be involved in collagen fiber assembly.

> Gene Ontology
 
Biological Process GO:0001933 negative regulation of protein phosphorylation
GO:0001974 blood vessel remodeling
GO:0006022 aminoglycan metabolic process
GO:0006023 aminoglycan biosynthetic process
GO:0006024 glycosaminoglycan biosynthetic process
GO:0006026 aminoglycan catabolic process
GO:0006027 glycosaminoglycan catabolic process
GO:0006029 proteoglycan metabolic process
GO:0006469 negative regulation of protein kinase activity
GO:0006790 sulfur compound metabolic process
GO:0007259 JAK-STAT cascade
GO:0009100 glycoprotein metabolic process
GO:0009101 glycoprotein biosynthetic process
GO:0018149 peptide cross-linking
GO:0018209 peptidyl-serine modification
GO:0019800 peptide cross-linking via chondroitin 4-sulfate glycosaminoglycan
GO:0030166 proteoglycan biosynthetic process
GO:0030198 extracellular matrix organization
GO:0030203 glycosaminoglycan metabolic process
GO:0030204 chondroitin sulfate metabolic process
GO:0030205 dermatan sulfate metabolic process
GO:0030206 chondroitin sulfate biosynthetic process
GO:0030207 chondroitin sulfate catabolic process
GO:0030208 dermatan sulfate biosynthetic process
GO:0033673 negative regulation of kinase activity
GO:0042326 negative regulation of phosphorylation
GO:0043062 extracellular structure organization
GO:0044272 sulfur compound biosynthetic process
GO:0044273 sulfur compound catabolic process
GO:0046425 regulation of JAK-STAT cascade
GO:0046426 negative regulation of JAK-STAT cascade
GO:0048771 tissue remodeling
GO:0050650 chondroitin sulfate proteoglycan biosynthetic process
GO:0050651 dermatan sulfate proteoglycan biosynthetic process
GO:0050654 chondroitin sulfate proteoglycan metabolic process
GO:0050655 dermatan sulfate proteoglycan metabolic process
GO:0051348 negative regulation of transferase activity
GO:0097696 STAT cascade
GO:1901136 carbohydrate derivative catabolic process
GO:1901565 organonitrogen compound catabolic process
GO:1902532 negative regulation of intracellular signal transduction
GO:1903510 mucopolysaccharide metabolic process
GO:1904892 regulation of STAT cascade
GO:1904893 negative regulation of STAT cascade
Molecular Function GO:0004857 enzyme inhibitor activity
GO:0004860 protein kinase inhibitor activity
GO:0005201 extracellular matrix structural constituent
GO:0005539 glycosaminoglycan binding
GO:0019207 kinase regulator activity
GO:0019210 kinase inhibitor activity
GO:0019887 protein kinase regulator activity
GO:0050840 extracellular matrix binding
Cellular Component GO:0005578 proteinaceous extracellular matrix
GO:0005775 vacuolar lumen
GO:0005796 Golgi lumen
GO:0030133 transport vesicle
GO:0042383 sarcolemma
GO:0043202 lysosomal lumen
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1971475: A tetrasaccharide linker sequence is required for GAG synthesis
R-HSA-2024101: CS/DS degradation
R-HSA-2022870: Chondroitin sulfate biosynthesis
R-HSA-1793185: Chondroitin sulfate/dermatan sulfate metabolism
R-HSA-4420332: Defective B3GALT6 causes EDSP2 and SEMDJL1
R-HSA-3560801: Defective B3GAT3 causes JDSSDHD
R-HSA-3560783: Defective B4GALT7 causes EDS, progeroid type
R-HSA-3595174: Defective CHST14 causes EDS, musculocontractural type
R-HSA-3595172: Defective CHST3 causes SEDCJD
R-HSA-3595177: Defective CHSY1 causes TPBS
R-HSA-2022923: Dermatan sulfate biosynthesis
R-HSA-1643685: Disease
R-HSA-3560782: Diseases associated with glycosaminoglycan metabolism
R-HSA-3781865: Diseases of glycosylation
R-HSA-3000178: ECM proteoglycans
R-HSA-1474244: Extracellular matrix organization
R-HSA-1630316: Glycosaminoglycan metabolism
R-HSA-1638091: Heparan sulfate/heparin (HS-GAG) metabolism
R-HSA-1430728: Metabolism
R-HSA-71387: Metabolism of carbohydrates
Summary
SymbolBGN
Namebiglycan
Aliases DSPG1; SLRR1A; biglycan proteoglycan; PG-S1; bone/cartilage proteoglycan I; bone/cartilage proteoglycan-I; d ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between BGN and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between BGN and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
29632715breast carcinomaPromote immunityFurthermore, BGN expression in HER-2/neu+ cells was accompanied by an increased expression of the proteoglycan decorin (DCN). Since recombinant DCN also elevated MHC class I surface expression in BGNlow/neg HER-2/neu+ cells, both proteoglycans might act synergistically.
Summary
SymbolBGN
Namebiglycan
Aliases DSPG1; SLRR1A; biglycan proteoglycan; PG-S1; bone/cartilage proteoglycan I; bone/cartilage proteoglycan-I; d ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of BGN in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolBGN
Namebiglycan
Aliases DSPG1; SLRR1A; biglycan proteoglycan; PG-S1; bone/cartilage proteoglycan I; bone/cartilage proteoglycan-I; d ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of BGN in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.9680.103
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.9320.563
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2550.914
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.3280.467
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.270.915
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.3950.908
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1130.852
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1180.953
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2720.907
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.0090.704
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.1930.562
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4360.0236
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of BGN in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.55.93.61
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolBGN
Namebiglycan
Aliases DSPG1; SLRR1A; biglycan proteoglycan; PG-S1; bone/cartilage proteoglycan I; bone/cartilage proteoglycan-I; d ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of BGN. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolBGN
Namebiglycan
Aliases DSPG1; SLRR1A; biglycan proteoglycan; PG-S1; bone/cartilage proteoglycan I; bone/cartilage proteoglycan-I; d ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of BGN. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by BGN.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolBGN
Namebiglycan
Aliases DSPG1; SLRR1A; biglycan proteoglycan; PG-S1; bone/cartilage proteoglycan I; bone/cartilage proteoglycan-I; d ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of BGN. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolBGN
Namebiglycan
Aliases DSPG1; SLRR1A; biglycan proteoglycan; PG-S1; bone/cartilage proteoglycan I; bone/cartilage proteoglycan-I; d ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of BGN expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolBGN
Namebiglycan
Aliases DSPG1; SLRR1A; biglycan proteoglycan; PG-S1; bone/cartilage proteoglycan I; bone/cartilage proteoglycan-I; d ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between BGN and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolBGN
Namebiglycan
Aliases DSPG1; SLRR1A; biglycan proteoglycan; PG-S1; bone/cartilage proteoglycan I; bone/cartilage proteoglycan-I; d ......
Chromosomal LocationXq28
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting BGN collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.